Author(s)

Mong Na Loi

Corresponding Author

Mong Na Loi

ABSTRACT

When people feel ill, most of us turn to medicine to help us get better. But there are years of intensive research behind each drug-it takes an average of 12 years for a drug to get from the lab to the medicine cabinet. Moreover, any new drug must undergo extensive testing, including laboratory and clinical trials, to ensure the safety and effectiveness of the drug before approval. According to statistics, 86% of drug candidates entering clinical trials will never enter the market. Traditional preclinical models, which are usually tested in human cells or animals, have many uncertainties, such as genetic variation between patients, and animal tests have the opportunity to show different responses from humans, adding to the challenge of predicting efficacy and toxicity under clinical trials. Furthermore, the use of laboratory animals, animal protection, ethical issues also become. So, the field of organ chips deserves attention and has the potential to be another way to save lives in a technologically advanced future. The following articles will explore in depth the potential of the multi-MOC (organ on a chip) model, especially in terms of potential contribution and expectations for COVID-19 (Coronavirus Disease 2019).

KEYWORDS

Multi-organ, COVID-19, New drug, chip model, Potential contribution